SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: DRS
Document Type: DRS
Date Filed: 2025-08-05
Accession Number: 0001641172-25-022123
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000164117225022123/filename1.htm

Chunk 65 of 82
Word Count: 1476
Character Count: 9065

Document Content:

written confirmation that they fall within the scope of the Addendum. Japan The securities have not been and will not be registered pursuant to Article 4, Paragraph 1 of the Financial Instruments and Exchange Act. Accordingly, none of the securities nor any interest therein may be offered or sold, directly or indirectly, in Japan or to, or for the benefit of, any “resident” of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for re-offering or resale, directly or indirectly, in Japan or to or for the benefit of a resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the Financial Instruments and Exchange Act and any other applicable laws, regulations and ministerial guidelines of Japan in effect at the relevant time. Singapore

This
prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, the underwriters have not offered
or sold any securities or caused the securities to be made the subject of an invitation for subscription or purchase and will not offer
or sell any securities or cause the securities to be made the subject of an invitation for subscription or purchase, and has not circulated
or distributed, nor will it circulate or distribute, this prospectus or any other document or material in connection with the offer or
sale, or invitation for subscription or purchase, of the securities, whether directly or indirectly, to any person in Singapore other
than:

an institutional investor (as defined in Section 4A of the Securities and Futures Act (Chapter
289) of Singapore, as modified or amended from time to time, or the SFA) pursuant to Section
274 of the SFA;

a relevant person (as defined in Section 275(2) of the SFA) pursuant to Section 275(1) of
the SFA, or any person pursuant to Section 275(1A) of the SFA, and in accordance with the
conditions specified in Section 275 of the SFA; or

(c)	otherwise
pursuant to, and in accordance with the conditions of, any other applicable provision of
the SFA.

Where
the securities are subscribed or purchased under Section 275 of the SFA by a relevant person which is:

corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the
sole business of which is to hold investments and the entire share capital of which is owned
by one or more individuals, each of whom is an accredited investor; or

trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments
and each beneficiary of the trust is an individual who is an accredited investor, securities
or securities-based derivatives contracts (each term as defined in Section 2(1) of the SFA)
of that corporation or the beneficiaries’ rights and interest (howsoever described)
in that trust shall not be transferred within six months after that corporation or that trust
has acquired the securities pursuant to an offer made under Section 275 of the SFA except:

an institutional investor or to a relevant person, or to any person arising from an offer
referred to in Section 275(1A) or Section 276(4)(i)(B) of the SFA;

ii.	where
no consideration is or will be given for the transfer;

iii.	where
the transfer is by operation of law;

specified in Section 276(7) of the SFA; or

specified in Regulation 37A of the Securities and Futures (Offers of Investments) (Securities
and Securities-based Derivatives Contracts) Regulations 2018.

Switzerland

The
securities may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any other stock
exchange or regulated trading facility in Switzerland. This prospectus does not constitute a prospectus within the meaning of, and has
been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of
Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any
other stock exchange or regulated trading facility in Switzerland. Neither this prospectus nor any other offering or marketing material
relating to the securities or this offering may be publicly distributed or otherwise made publicly available in Switzerland.

Neither
this prospectus nor any other offering or marketing material relating to this offering, the Company, the securities have been or will
be filed with or approved by any Swiss regulatory authority. In particular, this prospectus will not be filed with, and the offer of
securities will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA (FINMA), and the offer of securities has
not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or CISA. The investor protection afforded
to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of securities.

United
Kingdom

The
securities may not be made in the United Kingdom, except that an offer to the public of any securities may be made in the United Kingdom
at any time:

any legal entity which is a qualified investor as defined under Article 2 of the UK Prospectus
Regulation;

fewer than 150 natural or legal persons (other than qualified investors as defined under
Article 2 of the UK Prospectus Regulation), subject to obtaining the prior consent of the
Representative for any such offer; or

any other circumstances falling within Section 86 of the Financial Services and Markets Act
2000 (as amended, the “FSMA”);

provided
that no such offer of securities shall result in the requirement for the publication by us of a prospectus pursuant to Section 85
of the FSMA or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation.

For
the purposes of this provision, the expression an “offer to the public” in relation to the any securities in the United Kingdom
means the communication in any form and by any means of sufficient information on the terms of the offer and the securities to be offered
so as to enable an investor to decide to purchase or subscribe for the securities, and the expression “UK Prospectus Regulation”
means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018.

This
prospectus is only being distributed to and is only directed at: (1) persons who are outside the United Kingdom; (2) investment professionals
falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”);
or (3) high net worth companies, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (ed) of
the Order (all such persons falling within (1)-(3) together being referred to as “relevant persons”). The securities are
only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire the securities will be engaged
in only with, relevant persons. Any person who is not a relevant person should not act or rely on this prospectus or any of its contents.

LEGAL
MATTERS

The
validity of the issuance of the securities offered by us in this offering will be passed upon for us by Ellenoff Grossman &
Schole LLP, New York, New York. The underwriters are being represented by McGuireWoods LLP, New York, New York.

EXPERTS

CPAS, PLLC, our independent registered public accounting firm, has audited our consolidated balance sheets as of December 31, 2024 and
2023, and the related consolidated statements of operations, changes in stockholders’ equity and cash flows for the years ended
December 31, 2024 and 2023, as set forth in their report dated [  ]. We have included our consolidated financial statements
in this prospectus and in this registration statement in reliance on M&K CPA PLLC’s report given on their authority as experts
in accounting and auditing.

WHERE
YOU CAN FIND MORE INFORMATION

have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the shares of common stock offered
hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in
the registration statement or the exhibits filed therewith. For further information about us and the common stock offered hereby, reference
is made to the registration statement and the exhibits filed therewith. Statements contained in this prospectus concerning the contents
of any contract or any other document are not necessarily complete, please see the copy of the contract or document that has been filed
for the complete contents of that contract or document. Each statement in this prospectus relating to a contract or document filed as
an exhibit is qualified in all respects by the filed exhibit. The exhibits to the registration statement should be reviewed for the complete
contents of these contracts and documents.